FDA approves adjuvant treatment for RCC patients following nephrectomy
The FDA granted an additional indication for sunitinib on Nov. 16, 2017. This oral agent was approved for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomy. Approval was based on disease-free survival data from the S-TRAC study. (Data published December 2016, NEJM.).
Full prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021938s033lbl.pdf.
Is RADAR on your radar?
The RADAR and RADAR 2 working groups have developed consensus opinions for monitoring and managing men with advanced prostate cancer. These recommendations address when to image patients in order to proactively find M1 disease, as well as evaluate how to optimally layer therapies with unique mechanisms of action.
BPH: Expert commentary on the minimally invasive Prostatic Urethral Lift (PUL)
The Prostatic Urethral Lift (PUL) has been shown to rapidly and durably relieve men’s lower urinary tract symptoms – LUTS – secondary to benign prostatic hyperplasia (BPH) with minimal side effects.
Claus Roehrborn, M.D., professor and chair of the Department of Urology UT Southwestern Medical Center in Dallas and co-principal investigator for the L.I.F.T. clinical program, detailed findings from the largest, prospective, multicenter, randomized, controlled trial on the minimally invasive PUL to date at the 2017 American Urological Association annual meeting in Boston, May 12-16.